Secukinumab As A More Efficient Alternative For The Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis Versus Adalimumab And Golimumab From A Peruvian Perspective For Private And Public Health Schemes
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.886
https://www.valueinhealthjournal.com/article/S1098-3015(17)31220-2/fulltext
Title :
Secukinumab As A More Efficient Alternative For The Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis Versus Adalimumab And Golimumab From A Peruvian Perspective For Private And Public Health Schemes
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31220-2&doi=10.1016/j.jval.2017.08.886
First page :
A555
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
845